QuidelOrtho Corporation announced that the board has terminated Douglas Bryant as Chief Executive Officer. Mr. Bryant has also resigned from the Board, effective February 21, 2024. To ensure business continuity and effective leadership, the Board formed the Office of the Chief Executive Officer on February 17, 2024.

The Office of the CEO is led by the Company's Executive Vice President and Chief Commercial Officer, Michael Iskra, Executive Vice President and Chief Operating Officer, Robert Bujarski, and Chief Financial Officer, Joseph Busky. In this transition, Michael Iskra has been appointed as the Interim Chief Executive Officer, effective February 21, 2024. The Board has started a comprehensive search to identify a new Chief Executive Officer, considering both internal and external candidates.

Michael Iskra has over a decade of global executive leadership experience and more than 30 years of experience in the diagnostics and healthcare products and services industries. Michael brings significant knowledge and expertise across strategy, sales, marketing, operations and general management. Prior to his current role, Michael was Executive Vice President of Commercial Excellence and Strategy at Ortho Clinical Diagnostics Holdings plc from 2020 to 2022.